Etiology and outcome of acute liver failure: Experience from a liver transplantation centre in Montreal

Geneviève Tessier MD, Edith Villeneuve MD, Jean-Pierre Villeneuve MD

BACKGROUND: Acute liver failure is a rare condition in which massive liver injury is associated with the rapid development of hepatic encephalopathy. Although viral hepatitis and drug-induced liver injury are the most common causes, no specific etiology is found in a substantial proportion of cases reported from Europe and the United States.

AIM: To determine the etiology and outcome of patients with acute liver failure in the authors’ institution.

PATIENTS AND METHODS: The charts of 81 consecutive patients admitted to Saint-Luc between 1991 and 1999 were reviewed.

RESULTS: The etiology was viral in 27 cases (33.2%), toxic or drug-induced in 22 (27.2%), of unknown origin in 22 (27.2%) and due to various causes in 10 (12.3%) (autoimmune, vascular, cancer). Of the 81 patients, 16% survived without liver transplantation, and 84% died or underwent liver transplantation. Survival without liver transplantation differed according to the mode of presentation: the survival rate was 27% in patients with hyperacute liver failure, 7% in those with acute liver failure and 0% in those with subacute liver failure. Among the 38 patients who underwent liver transplantation, survival one year after transplantation was 71%. In the 30 patients who died without liver transplantation, the main causes of death were cerebral edema and sepsis.

CONCLUSIONS: Acute liver failure is associated with a high mortality, and liver transplantation is the treatment of choice. In a significant proportion of cases, the etiology remains undetermined and is probably related to yet unidentified hepatotropic viruses.

Key Words: Acute liver failure; Fulminant hepatitis; Liver transplantation

Étiologie et pronostic de l’insuffisance hépatique aiguë : Expérience menée dans un centre de transplantation hépatique de Montréal

HISTORIQUE : L’insuffisance hépatique aiguë est un problème de santé rare, caractérisé par une atteinte massive du foie associée au développement rapide d’une encéphalopathie d’origine hépatique. Bien que l’hépatite virale et que l’atteinte hépatique d’origine médicamenteuse en soient les principales causes, aucune étiologie spécifique n’a été arrêtée dans une proportion importante de cas signalés en Europe et aux États-Unis.

BUT : Déterminer l’étiologie et l’évolution des cas d’insuffisance hépatique aiguë traités dans l’établissement des auteurs.


RÉSULTATS : L’étiologie s’est révélée virale dans 27 cas (33,2 %), toxique ou d’origine médicamenteuse dans 22 cas (27,2 %), d’origine inconnue dans 22 cas (27,2 %) et de causes diverses dans 10 cas (12,3 %) (cause auto-immune, vasculaire, ou cancer). Parmi les 81 patients, 16 % ont survécu sans transplantation hépatique et 84 % sont décédés et ont dû subir une transplantation hépatique. La survie sans transplantation hépatique a différé selon le mode de présentation. Le taux de survie a été de
Acute liver failure is an uncommon but dramatic syndrome that is defined as an acute, often fatal illness that results from massive hepatic necrosis (1). The hepatic damage leads rapidly to encephalopathy, coagulopathy, cerebral edema and multiorgan failure. The prognosis is poor, with a mortality rate of about 80% without liver transplantation.

Recently, a few papers have described the epidemiology of acute liver failure. Most of the reports are from Europe and the United States (2-4). In the United States, the annual incidence of acute liver failure has been estimated to be approximately one in 100,000 (5). Applying this figure to Canada, about 300 cases would be expected to occur annually in Canada, and 70 cases in the province of Quebec. To our knowledge, large series of acute liver failure in Canada or Quebec have not been previously reported.

The aim of the present study was to describe the etiology and outcome of acute liver failure in a referral centre for liver disease in the Montreal area.

**PATIENTS AND METHODS**

Data were retrospectively collected on 81 patients admitted to Hôpital Saint-Luc with a diagnosis of acute liver failure, during a nine-year period from January 1, 1991 to December 31, 1999. Patients with known underlying liver disease were excluded from the study.

Acute liver failure was classified according to O'Grady et al (6). Hyperacute liver failure is defined as encephalopathy developing within seven days of the onset of jaundice. Acute liver failure is encephalopathy developing within eight to 28 days of the onset of jaundice, while in subacute liver failure, the encephalopathy occurs four to 26 weeks after the onset of jaundice.

During the study period, all patients with acute liver failure were admitted to a general intensive care unit. The severity of hepatic encephalopathy was divided into four grades (7). Intracranial pressure monitoring was not used routinely, but a subdural transducer was inserted in 11 patients during the study period. Hemocultures and cultures of all available fluids were performed routinely, but prophylactic administration of antibiotics was not used systematically. In patients eligible for liver transplantation, the decision to list them for transplantation was made by a medicosurgical team experienced in the care of these patients. In general, patients with hyperacute liver failure were listed when they developed grade IV hepatic encephalopathy and those with acute liver failure were listed when they developed grade III encephalopathy. Patients with subacute liver failure and without grade III or IV encephalopathy were also listed when no improvement was observed after a seven- to 10-day period of observation.

The outcome of patients with acute liver failure at the Hôpital Saint-Luc, Centre Hospitalier de l'Université de Montréal, Québec, was compared with that predicted by the prognostic model developed at King's College Hospital (7). According to this model, in patients with acetaminophen-induced acute liver failure, the presence of an arterial blood pH less than 7.30 or of hepatic encephalopathy grade III or IV with a serum creatinine greater than 300 µmol/L and an International Normalized Ratio (INR) higher than 6.5 predicts a high likelihood of death. In patients with nonacetyaminophen-induced liver failure, a high likelihood of death is predicted by an INR higher than 6.5, or the presence of any three of the following variables: age younger

**TABLE 1**

Etiology of acute liver failure in 81 consecutive cases

<table>
<thead>
<tr>
<th>Etiology</th>
<th>n (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Viral hepatitis</td>
<td>27 (33.3)</td>
</tr>
<tr>
<td>Hepatitis A</td>
<td>4</td>
</tr>
<tr>
<td>Hepatitis B</td>
<td>18</td>
</tr>
<tr>
<td>Hepatitis B + D</td>
<td>2</td>
</tr>
<tr>
<td>Herpes simplex</td>
<td>3</td>
</tr>
<tr>
<td>Drugs and toxins</td>
<td>22 (27.2)</td>
</tr>
<tr>
<td>Acetaminophen</td>
<td>12</td>
</tr>
<tr>
<td>Isoniazide</td>
<td>2</td>
</tr>
<tr>
<td>Salazopyrime</td>
<td>1</td>
</tr>
<tr>
<td>Erythromycin</td>
<td>1</td>
</tr>
<tr>
<td>Azithromycin</td>
<td>1</td>
</tr>
<tr>
<td>Cyproterone</td>
<td>1</td>
</tr>
<tr>
<td>Naproxen</td>
<td>1</td>
</tr>
<tr>
<td>Germander</td>
<td>1</td>
</tr>
<tr>
<td>Amanita verosa</td>
<td>1</td>
</tr>
<tr>
<td>Carbon tetrachloride</td>
<td>1</td>
</tr>
<tr>
<td>Miscellaneous</td>
<td>10 (12.3)</td>
</tr>
<tr>
<td>Autoimmune hepatitis</td>
<td>6</td>
</tr>
<tr>
<td>Budd-Chiari</td>
<td>2</td>
</tr>
<tr>
<td>Heat stroke</td>
<td>1</td>
</tr>
<tr>
<td>Lymphoma</td>
<td>1</td>
</tr>
<tr>
<td>Cryptogenic</td>
<td>22 (27.2)</td>
</tr>
</tbody>
</table>

CONCLUSIONS: L'insuffisance hépatique aiguë est associée à un fort taux de mortalité et la transplantation hépatique est le traitement de choix. Dans une proportion significative de cas, l'étiologie reste à déterminer et procède probablement de virus hépatotropiques pour l'instant non identifiés.
than 10 years or older than 40 years, acute or subacute liver failure, INR higher than 3.5, serum bilirubin concentration higher than 300 µmol/L and etiology due to non-A, non-B hepatitis or idiosyncratic drug reactions.

RESULTS

The charts of 81 consecutive patients admitted to the Hôpital Saint-Luc, Centre Hospitalier de l’Université de Montréal, with a diagnosis of acute liver failure during a nine-year period were reviewed. There were 47 men and 34 women, and the mean age was 38.5 years. The etiology of fulminant hepatic failure is shown in Table 1. Overall, viral hepatitis was the most common cause (33.3%), followed by cryptogenic (27.2%) and drug- or toxin-induced liver injury (27.2%). The miscellaneous category (12.3%) included autoimmune hepatitis, Budd-Chiari syndrome, heat stroke and lymphoma. Among cases of viral hepatitis, hepatitis B was the most common etiology, whereas acetaminophen was the most common cause of drug-induced liver injury.

The outcomes of the 81 patients are shown in Figure 1. Fifty-one patients were listed for liver transplantation: 38 of them underwent liver transplantation after a median waiting time of two days (range zero to 22 days), eight patients died or developed contraindications to liver transplantation and died before a liver became available (median waiting time three days, range zero to nine days), and five patients improved spontaneously and were removed from the list. Thirty patients were not listed for liver transplantation: eight did not progress to grade III or IV encephalopathy and recovered spontaneously, and 22 had contraindications to liver transplantation. Thus, overall, 47% underwent liver transplantation, 16% recovered spontaneously and 37% died without transplantation.

For the 22 patients who died without being listed for transplantation, contraindications to liver transplantation were as follows: infection (n=7), substance abuse (n=5), psychiatric disease (n=3), cancer (n=2), refusal of liver transplant (n=1) and rapid death from complications of acute liver failure (one multiorgan failure, two massive bleeding and one cerebral edema).

The outcomes of patients according to the etiology of liver failure are shown in Figure 2. Acetaminophen was associated with the highest rate of survival without liver transplantation, whereas spontaneous survival was only 5% in patients with cryptogenic acute liver failure. The outcomes according to the mode of presentation (hyperacute, acute, subacute) are shown in Figure 3. The highest spontaneous survival rate was seen in patients with hyperacute liver failure, and the lowest in those with subacute liver failure.

In the 30 patients who did not receive a liver transplantation and died, liver failure with cerebral edema was the most common cause of death (n=21), but sepsis was also an important cause of mortality (n=5). Three patients died of bleeding secondary to severe coagulopathy, and one of multiorgan failure.

Among the 38 patients who underwent liver transplantation, 27 (71%) survived and were alive at one year after
transplantation, whereas 11 (29%) died. There was a trend for an improvement in the results of liver transplantation over time: during the 1991 to 1995 period, one-year survival was 59% (10 of 17 cases), whereas in the 1996 to 1999 period, it increased to 76% (16 of 21 cases). The causes of death included sepsis (n=6), cerebral edema (n=1), acute liver rejection (n=1) and cardiac failure (n=1), whereas two patients with cryptogenic acute liver failure developed recurrent fulminant hepatitis in the transplanted liver, as confirmed by histology, and died. Eight of the 38 patients who received transplants underwent a second liver transplantation because of hepatic artery thrombosis (n=6), primary graft nonfunction (n=1) or recurrent fulminant hepatitis (n=1). Only three of eight survived.

To evaluate the validity of the King’s criteria to predict outcome, patients who underwent liver transplantation were excluded from analysis, because the outcomes of these patients without transplantation could not be predicted with certainty. The King’s criteria were present in 31 of 38 patients who underwent liver transplantation. Among the 43 patients who did not receive a transplant, 30 died and 13 survived. Among patients with nonacetaminophen-induced acute liver failure, the King’s criteria were present in 21 of the 27 patients who died, and absent in five of the nine patients who survived. Thus, mortality was 84% when criteria were present (positive predictive value) and 55% when criteria were absent (100 minus negative predictive value).

In patients with acetaminophen-induced acute liver failure, the King’s criteria were present in the three patients who died, and absent in three of the four survivors. The predictive accuracy of the King’s criteria is summarized in Table 2, and compared with that reported in other publications. Overall, the predictive accuracy was similar to that reported by Pauwels et al (8) and Anand et al (9), but lower than that given in the original description of the model by O’Grady et al (7).

**DISCUSSION**

Acute liver failure is an uncommon disease, and few data are available on the etiology and outcome of this condition in Canada (10). In the present study, cryptogenic hepatitis was the most common cause of acute liver failure (27% of cases), followed by hepatitis B (22%) and acetaminophen overdose (15%). The frequency of acetaminophen-induced acute liver failure in the present study is considerably less than that observed in the United Kingdom, where it accounts for 50% to 75% of all cases of acute liver failure (3,11). By contrast, acetaminophen overdose only accounts for 2% of cases in France (2), whereas in the United States, a 20% frequency has been reported (4), similar to that of the present study.

Cryptogenic acute liver failure accounted for 27% of cases in our study. A similar, although somewhat lower proportion, of cryptogenic cases (15% to 20%) has been reported in France, the United Kingdom and the United States (2-4). Evidence is accumulating to implicate yet unidentified hepatotropic viruses in cryptogenic acute liver failure (12). In a prospective study of British patients with cryptogenic acute liver failure, virus-like particles were detected in the cytoplasm of hepatocytes (13). In addition, after liver transplantation, liver failure recurred in some patients around seven days after grafting, with the appear-
tessier.qxd 10/15/2002 4:22 PM Page 676

Tessier et al

ance of the same virus-like particles in the graft (13). In the present study, acute liver failure occurred in the graft in two patients with cryptogenic fulminant hepatitis. In one of them, the disease recurred a second time after a second liver transplantation. Both patients died from disease recurrence. These observations provide support for the existence of yet unidentified transmissible agents in some cases of acute liver failure.

Spontaneous survival without liver transplantation was 16% in the present series, similar to the 25% figure reported by Schiodt et al (4). Acetaminophen overdose was associated with a relatively favourable outcome, whereas patients with cryptogenic liver failure had a poorer outcome. As reported by O'Grady et al (6), patients with acute or subacute liver failure had a much poorer prognosis than those with hyperacute liver failure. Among patients who died without liver transplantation, cerebral edema was the major cause of death, but sepsis also contributed to mortality. After liver transplantation, sepsis was also the major cause of death. Prophylactic systemic antibiotics reduce the risk of infection (14), but systematic cultures remain mandatory because early recognition of infection can be difficult in these patients.

The relatively high transplantation rate (47%) in our series likely reflects a selection bias from a transplantation centre, because it is estimated that only 10% of patients with acute liver failure receive a liver graft in North America (5). Emergency liver transplantation has changed the outlook of acute liver failure, and the 71% one-year survival rate in the present series is comparable with that of others (10). The rate of retransplantation in the present study (eight of 38 [21%]) is higher than the 13% rate reported by Bismuth et al (15).

In patients with acute liver failure, early identification of those likely to die is essential so that liver transplantation can be done before complications such as cerebral edema, severe infection or multiorgan failure preclude the procedure. In 1989, O'Grady and colleagues (7) from the King's College Hospital in London, United Kingdom, proposed criteria for the early identification of patients having a high probability of death. The King's criteria are considered to be the best and most easily obtained criteria (15). In patients with acetaminophen-induced acute liver failure, the King's criteria are clearly useful: their positive predictive value for death is about 85%, whereas the overall mortality ranges from 35% to 45%. Our data, although in a very limited number of patients, support this view.

In patients with nonacetaminophen induced acute liver failure, the present data suggest that the King's criteria are less useful: their positive predictive value was only slightly higher than the overall mortality in this group. Their negative predictive value was low, indicating that a significant proportion of patients not selected by these criteria will not survive without liver transplantation. Thus, a strategy where patients with grade III or IV encephalopathy are listed for transplantation, as in our centre, probably yields results similar to one based on King's criteria (8,16-18).

SUMMARY

The present study indicates that the etiology and standard of care for acute hepatic failure in Montreal is similar to that observed in other North American and European centres. The high proportion of cases with cryptogenic acute liver failure stresses the need to search for new viruses. A Canadian registry, and a bank of liver tissue and serum in cases of fulminant hepatic failure would provide opportunities for research on the etiology and management of this rare and catastrophic condition.

REFERENCES
